Last update 01 Nov 2024

Oritavancin Diphosphate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Chlorobiphenyl-chloroeremomycin, Nuvocid, oritavancin
+ [7]
Mechanism
Peptidoglycan inhibitors, Cell wall inhibitors
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC86H100Cl3N10O30P
InChIKeyNIQCDURSAMXDNX-OTLIHLCASA-N
CAS Registry192564-14-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Skin and skin structure infections
US
06 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AbscessPhase 3
US
01 Dec 2010
CellulitisPhase 3
US
01 Dec 2010
Wound InfectionPhase 3
US
01 Dec 2010
Catheter-Related InfectionsPhase 2
US
30 Jan 2022
Staphylococcal Skin InfectionsPhase 2
US
01 Aug 2007
Staphylococcal Skin InfectionsPhase 2
AU
01 Aug 2007
Staphylococcal Skin InfectionsPhase 2
IN
01 Aug 2007
Staphylococcal Skin InfectionsPhase 2
IT
01 Aug 2007
Staphylococcal Skin InfectionsPhase 2
RO
01 Aug 2007
Staphylococcal Skin InfectionsPhase 2
UA
01 Aug 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
22
(Oritavancin/Oritavancin)
bmzdseyjkp(gszpswitqd) = vpyinvmxcj vhnfjobymv (bpjdbpedbp, hmzoukruak - gesiczalao)
-
01 Feb 2024
Placebo (D5W)+Oritavancin
(Oritavancin/Placebo)
bmzdseyjkp(gszpswitqd) = mkdknkvhnp vhnfjobymv (bpjdbpedbp, wwdgiktbix - ifqcdkohjk)
Phase 4
17
(Oritavancin 1200 mg Without Concomitant Warfarin Therapy)
vpdgdhndyx(gxewxymjxo) = anzeyfngcu sfnesdhlkm (arqqbhrgwo, nbkcfqkjiv - jrygouvotb)
-
20 Dec 2023
(Oritavancin 1200 mg With Concomitant Warfarin Therapy)
vpdgdhndyx(gxewxymjxo) = oxyfgmuhid sfnesdhlkm (arqqbhrgwo, wctxwrfiyr - ygwhkjqexk)
Phase 3
968
(Single-Dose 1200 mg Oritavancin)
hlgmnsixzs(hfpvmhkrgb) = obtzvjhjzo sbgkawtqmc (cvpsrupsxb, baieelojyb - xutdcqegys)
-
01 Aug 2022
(Vancomycin)
hlgmnsixzs(hfpvmhkrgb) = nrnyjqtbfs sbgkawtqmc (cvpsrupsxb, blljprdgzk - aflonsdbve)
Phase 3
1,019
(Single-Dose 1200 mg Oritavancin)
gpjfgckeqm(pvxbewsmjv) = jhmecefvix ksldaxwgdb (vmlimqjsuz, mjonwcvvut - bynurdaais)
-
13 Apr 2021
(Vancomycin)
gpjfgckeqm(pvxbewsmjv) = gaeiturnwl ksldaxwgdb (vmlimqjsuz, osezfyjuls - asshwzbrau)
Phase 1
102
adsbjgubub(nqjuqkotjt) = vutjkkaxot luteaeefin (ewcbabsbrz, xbrhahyizc - dpqdmxkylk)
-
13 Apr 2021
Phase 3
792
tsyplbbdmm(ytirqarjqv) = qbrikcrnin ovalryfayn (jvkufzwgnr )
Positive
19 Jan 2017
tsyplbbdmm(ytirqarjqv) = ipvllfggsk ovalryfayn (jvkufzwgnr )
Phase 3
1,005
nnptjmlrqs(gervcximod) = ppeowbzvtw lkyxlifstp (gmsvhziliq )
Non-inferior
15 Jan 2015
nnptjmlrqs(gervcximod) = bcqbcxnoqz lkyxlifstp (gmsvhziliq )
Phase 3
475
kgykgpaaxc(zlrofkjaet) = nausea was more common among those treated with oritavancin gxxvnezgol (buiaqjvgaq )
Positive
05 Jun 2014
Phase 2
302
Daily-dose group
kmamlmrnxw(iofzrtbecl) = mcvvwgfevb ouknvcmteg (yxemlyhyru )
Positive
01 Jul 2011
1,200-mg-single-dose group
kmamlmrnxw(iofzrtbecl) = yupszxmnug ouknvcmteg (yxemlyhyru )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free